Knight Therapeutics to reveal Q4 and 2025 full-year financial results on March 19
Knight Therapeutics Inc. will announce its financial results for the fourth quarter and full year of 2025 on Thursday, March 19, 2026. The Montreal-based company, which trades on the TSX under the symbol GUD, will also host a conference call and webcast to discuss the performance in detail.
The company's earnings release will cover its operations across Canada and Latin America. Its portfolio includes over 10 pharmaceutical products, such as Minjuvi, Pemazyre, Akynzeo, and JAKAFI, alongside newer launches like ONICIT in Brazil and Mexico. Knight Therapeutics also manages regional subsidiaries under United Medical, Biotoscana Farma, and Laboratorio LKM.
The conference call begins at 8:30 a.m. ET on March 19. Participants can join via toll-free number (1-888-699-1199) or internationally (1-416-945-7677). An audio webcast will stream live on the company's website, www.knighttx.com, as well as on www.globenewswire.com.
For those unable to attend, an archived replay will remain available for 30 days on the company's site. Regulatory filings can be found on www.sedarplus.ca, while further corporate information is accessible at www.knighttx.com.
Knight Therapeutics continues to expand its presence in Canadian and Latin American markets. The upcoming financial report will provide insights into its latest commercial performance and strategic direction. Investors and analysts can access the details through the scheduled call and online resources.
